Foghorn Therapeutics annual current ratio
2019
2020
2021
2022
2023
2024
2025
Foghorn Therapeutics Current Ratio Growth & History (FHTX)
Foghorn Therapeutics's current ratio was 2.73 for fiscal 2025.
View full Foghorn Therapeutics company overviewFoghorn Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.73 | −0.99 | −26.66% |
| 2024 | 2024-12-31 | 3.73 | −0.38 | −9.35% |
| 2023 | 2023-12-31 | 4.11 | −2.26 | −35.43% |
| 2022 | 2022-12-31 | 6.37 | −3.07 | −32.56% |
| 2021 | 2021-12-31 | 9.44 | −0.68 | −6.72% |
| 2020 | 2020-12-31 | 10.12 | 8.78 | +658.16% |
| 2019 | 2019-12-31 | 1.33 | — | — |
Foghorn Therapeutics quarterly current ratio
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.36 | 0.74 | +28.29% |
| Q1 2026 | 2026-03-31 | 2.92 | −0.24 | −7.63% |
| Q4 2025 | 2025-12-31 | 2.73 | −0.99 | −26.66% |
| Q3 2025 | 2025-09-30 | 2.16 | −2.61 | −54.67% |
| Q2 2025 | 2025-06-30 | 2.62 | −3.07 | −53.97% |
| Q1 2025 | 2025-03-31 | 3.16 | −0.90 | −22.19% |
| Q4 2024 | 2024-12-31 | 3.73 | −0.38 | −9.35% |
| Q3 2024 | 2024-09-30 | 4.77 | −0.33 | −6.47% |
| Q2 2024 | 2024-06-30 | 5.69 | 0.56 | +11.00% |
| Q1 2024 | 2024-03-31 | 4.06 | −1.69 | −29.32% |
| Q4 2023 | 2023-12-31 | 4.11 | −2.26 | −35.43% |
| Q3 2023 | 2023-09-30 | 5.10 | −1.74 | −25.41% |
| Q2 2023 | 2023-06-30 | 5.13 | −3.21 | −38.51% |
| Q1 2023 | 2023-03-31 | 5.75 | −3.16 | −35.49% |
| Q4 2022 | 2022-12-31 | 6.37 | −3.07 | −32.56% |
| Q3 2022 | 2022-09-30 | 6.84 | 0.42 | +6.51% |
| Q2 2022 | 2022-06-30 | 8.34 | −0.47 | −5.37% |
| Q1 2022 | 2022-03-31 | 8.91 | −1.21 | −11.98% |
| Q4 2021 | 2021-12-31 | 9.44 | −0.68 | −6.72% |
| Q3 2021 | 2021-09-30 | 6.42 | 2.77 | +75.96% |
| Q2 2021 | 2021-06-30 | 8.81 | — | — |
| Q1 2021 | 2021-03-31 | 10.12 | — | — |
| Q4 2020 | 2020-12-31 | 10.12 | 8.78 | +658.16% |
| Q3 2020 | 2020-09-30 | 3.65 | — | — |
| Q4 2019 | 2019-12-31 | 1.33 | — | — |
Foghorn Therapeutics current ratio trends
Over the last five fiscal years, Foghorn Therapeutics's current ratio decreased from 10.12 to 2.73, a change of −7.39. The latest reported quarter, Q2 2026, shows 3.36.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Foghorn Therapeutics source filings ↗